|
Feature
|
Cohort A (Italy)
|
Cohort B (USA)
|
|---|
|
Average copies/μL ± SD
|
Average copies/μL ± SD
|
|---|
|
(n = number of patients)
|
(n = number of patients)
|
|---|
|
Tumor size (pT)
|
pT1
|
108.7 ± 78.0 (n = 19)
|
98.6 ± 47.3 (n = 28)
|
|
pT2
|
97.3 ± 55.9 (n = 6)
|
143.4 ± 70.3 (n = 27)
|
|
pT3
|
/
|
75.0 ± 11.9 (n = 4)
|
|
Lymph node involvement (pN)
|
pN0
|
88.7 ± 37.2 (n = 18)
|
101.2 ± 54.6 (n = 35)
|
|
pN1-2-3
|
113.3 ± 89.4 (n = 7)
|
145.2 ± 70.8 (n = 23)
|
|
Stage
|
I
|
82.9 ± 28.5 (n = 14)
|
91.3 ± 45.9 (n = 23)
|
|
II
|
107.7 ± 79.9 (n = 10)
|
128.0 ± 61.8 (n = 25)
|
|
III
|
134.0 (n = 1)
|
130.5 ± 60.2 (n = 8)
|
|
IV
|
/
|
242.2 ± 110.3 (n = 2)
|
|
Grade
|
I
|
80.8 ± 36.5 (n = 5)
|
114.9 ± 43.2 (n = 11)
|
|
II
|
112.7 ± 88.6 (n = 18)
|
91.2 ± 58.8 (n = 13)
|
|
III
|
105.0 ± 54.3 (n = 5)
|
136.0 ± 74.81 (n = 34)
|
|
ER/PR status
|
ER+/PR+
|
142.1 ± 98.44 (n = 17)
|
115.0 ± 60.1 (n = 35)
|
|
ER-/PR-
|
74.0 (n = 1)
|
131.9 ± 89.4 (n = 16)
|
|
HER2/neu receptor
|
Positive
|
103.7 ± 80.8 (n = 3)
|
112.9 ± 65.5 (n = 11)
|
|
Negative
|
115.8 ± 88.4 (n = 25)
|
145.8 ± 75.0 (n = 44)
|
|
Triple Negatives
|
ER-/PR-/HER2-
|
74.0 (n = 1)
|
117.8 ± 90.2 (n = 9)
|
|
Others
|
118.2 ± 85.61 (n = 27)
|
121.5 ± 63.36 (n = 49)
|
-
ER estrogen receptor, PR progesterone receptor, HER2/neu human epidermal growth factor receptor 2
